


 Cite this: *RSC Adv.*, 2021, **11**, 17064

# Modelling drug adsorption in metal–organic frameworks: the role of solvent†

 Abhishek T. Sose,  ‡<sup>a</sup> Hannah D. Cornell,  ‡<sup>b</sup> Bradley J. Gibbons, <sup>b</sup>  
 Ashley A. Burris, <sup>b</sup> Amanda J. Morris <sup>\*b</sup> and Sanket A. Deshmukh <sup>\*,a</sup>

Solvent plays a key role in biological functions, catalysis, and drug delivery. Metal–organic frameworks (MOFs) due to their tunable functionalities, porosities and surface areas have been recently used as drug delivery vehicles. To investigate the effect of solvent on drug adsorption in MOFs, we have performed integrated computational and experimental studies in selected biocompatible MOFs, specifically, UiO-AZB, HKUST-1 (or CuBTC) and NH<sub>2</sub>-MIL-53(Al). The adsorption of three drugs, namely, 5-fluorouracil (5-FU), ibuprofen (IBU), and hydroxyurea (HU) were performed in the presence and absence of the ethanol. Our computational predictions, at 1 atmospheric pressure, showed a reasonable agreement with experimental studies performed in the presence of ethanol. We find that in the presence of ethanol the drug molecules were adsorbed at the interface of solvent and MOFs. Moreover, the computationally calculated adsorption isotherms suggested that the drug adsorption was driven by electrostatic interactions at lower pressures (<10<sup>−4</sup> Pa). Our computational predictions in the absence of ethanol were higher compared to those in the presence of ethanol. The MOF–adsorbate interaction ( $U_{HA}$ ) energy decreased with decrease in the size of a drug molecule in all three MOFs at all simulated pressures. At high pressure the interaction energy increases with increase in the MOFs pore size as the number of molecules adsorbed increases. Thus, our research shows the important role played by solvent in drug adsorption and suggests that it is critical to consider solvent while performing computational studies.

 Received 5th March 2021  
 Accepted 30th April 2021

DOI: 10.1039/d1ra01746b

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

## Introduction

Solvent has shown its prime importance in biological functions, polymer science, catalysis, and biomedical applications.<sup>1–7</sup> For example, in drug delivery vehicle (DDV) development, the interactions between the drug and relevant body fluids (solvent) play a critical role in driving drug release from the carrier.<sup>8</sup> Similarly, the drug loading in a DDV is determined by the interactions between solvent and drugs, between solvent and the DDV, and between drug and DDV.<sup>9–11</sup> At present, our atomic-level understanding of drug loading in DDVs, such as polymers and porous materials, is very limited. Specifically, the precise role of the interactions between solvent and the drugs, and between solvent and DDV is unknown.<sup>12–14</sup> Without knowledge of these interactions, it is difficult to understand if the drug adsorption occurs at the interface between solvent and the DDV or if the drug molecules reside primarily in the pore volume of

the DDV. An understanding of the interplay of drug, solvent, and carrier interactions is, therefore, important for the design of new DDVs with higher uptake and efficient drug release.

Recently, metal–organic frameworks (MOFs) have been used in the field of catalysis, gas storage, and drug delivery due to their adjustable functionalities, tunable porosities, and high surface area.<sup>13,15–21</sup> In these applications, it has been reported that solvent plays an important role in determining the stability and function (*e.g.* adsorption capacity) of a MOF.<sup>22,23</sup> A number of experimental and computational studies also show that MOFs have higher drug storage capacity than other porous materials due to high surface area and the formation of non-bonded interactions with drugs.<sup>17</sup> Grand canonical Monte Carlo (GCMC) simulations have been used to study drug adsorption both in the presence and absence of solvent at the molecular-level.<sup>13,15,24–28</sup> For example, adsorption of the anti-cancer drugs 5-FU and HU in ZIFs was studied by Gomar *et al.*,<sup>25</sup> while Erucar *et al.* performed a computational study on methotrexate and 5-FU uptake in MOF-74 in the absence of solvent.<sup>15</sup> Bernini *et al.* employed GCMC simulations to study the adsorption of IBU in a series of bio-compatible MOFs.<sup>24</sup> In the computational studies performed in the absence of solvent, drug adsorption is often overestimated compared to experiment, which uses solvent to dissolve and adsorb drugs in MOFs.

<sup>a</sup>Department of Chemical Engineering, Virginia Tech, Blacksburg, VA, 24060, USA. E-mail: [sanketad@vt.edu](mailto:sanketad@vt.edu)
<sup>b</sup>Department of Chemistry, Virginia Tech, Blacksburg, VA, , 24060, USA. E-mail: [ajmorris@vt.edu](mailto:ajmorris@vt.edu)

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1ra01746b

‡ Both authors contributed equally.



**Table 1** Textural properties of the selected MOFs. The simulated uptake data is collected at 300 K and  $10^5$  Pa, similar to experimental conditions in the presence of ethanol

	Calculated void volume ( $\text{cm}^3 \text{g}^{-1}$ )	Calculated pore-cavity size (Å)	Calculated surface area ( $\text{m}^2 \text{g}^{-1}$ )	Experimental surface area ( $\text{m}^2 \text{g}^{-1}$ )	Literature reported surface area ( $\text{m}^2 \text{g}^{-1}$ )	Literature reported void volume ( $\text{cm}^3 \text{g}^{-1}$ )
HKUST-1	0.9066	5.1, 10.6, 12.2	2365	1830	1507 (ref. 36), 1843 (ref. 37), 1600 (ref. 38), 1740 (ref. 39)	0.75 (ref. 40), 0.79 (ref. 41)
NH <sub>2</sub> -MIL-53(Al)	0.6272	6.36	1395	725	675 (ref. 42), 712 (ref. 43), 947 (ref. 44)	0.83 (ref. 45)
UiO-AZB	1.4057	10.8, 11.9, 13.7	3692	1959	903–2687 (ref. 32)	—

The differences are attributed to experimental limitations, such as the non-accessibility of the cavities and poor activation of the MOF samples.<sup>13</sup> However, Proenza *et al.* performed GCMC simulations to study adsorption of 5-FU and caffeine (CAF) in ZIF-8 analogs, and identified that the lack of consideration for solvent and surface effects in adsorption study contributes majorly towards the overestimation of drug adsorption.<sup>29</sup>

## Result and discussion

Motivated by elucidating the importance of solvent on drug adsorption in MOFs at the molecular-level, we performed a combined computational and experimental study of drug adsorption in MOFs in the presence of explicit solvent. Specifically, we employ GCMC simulations to study adsorption of 5-FU, IBU, and HU in three MOFs of interest, namely, HKUST-1, NH<sub>2</sub>-MIL-53 and UiO-AZB in the presence of ethanol. HKUST-1 and NH<sub>2</sub>-MIL-53 were selected because of their established biocompatibility and wide-use throughout the literature.<sup>30,31</sup> UiO-AZB is a light-responsive framework developed in our lab that shows promise as a versatile drug delivery vehicle.<sup>32</sup> Tables S1–S3 and Fig. S1 in Section S1† discuss details on drug and solvent molecules used in our study. Table 1 summarizes the textural properties of these MOFs and a detailed computational and experimental methodology used to calculate the properties is listed in Section S2 of the ESI.† The molecular-level structures of all three MOFs and force-field parameters are shown in Fig. S2 and Tables S5–S7 in the ESI.† As can be seen from Table 1, the calculated surface area for all three MOFs is higher than experimental measurements. This is expected, as simulations are performed on perfect crystalline frameworks and do not

account for defects.<sup>33</sup> The differences in pore volume can be accounted for with scaling factors that reconcile experimental and simulated adsorption.<sup>33,34</sup> In addition, Epley *et al.* highlights differences in the experimental and theoretical surface area observations in UiO-AZB, which can be due to the introduction of macroporosity within the samples.<sup>32</sup> The pore size distribution (PSD) suggests that the HKUST-1, NH<sub>2</sub>-MIL-53, and UiO-AZB are microporous (pore size upto 20 Å).<sup>35</sup> More details on PSD calculations can be found in the ESI, Section S2.†

To probe the effect of solvent, we performed GCMC simulations in the absence and presence of ethanol. Table 2 lists the maximum drug uptake calculated with GCMC simulations and experimentally measured at 300 K and 1 atm. To study drug adsorption in the presence of ethanol, initially, GCMC simulations were performed to evaluate the number of ethanol molecules adsorbed in the MOFs at 1 bar and 300 K for 500 000 steps. The adsorption of ethanol in HKUST-1, NH<sub>2</sub>-MIL-53 and UiO-AZB was found out to be 509.1 ( $\text{mg g}^{-1}$ ), 296.67 ( $\text{mg g}^{-1}$ ) and 920.45 ( $\text{mg g}^{-1}$ ), respectively. This corresponds to 107  $\text{mol uc}^{-1}$ , 5.75  $\text{mol uc}^{-1}$  and 183  $\text{mol uc}^{-1}$  in HKUST-1, NH<sub>2</sub>-MIL-53 and UiO-AZB, respectively. The number of molecules of ethanol obtained from these simulations were used as a starting number of molecules in initial configuration for drug adsorption studies in the presence of ethanol. During these two components (both drug and ethanol) simulations, equal probabilities of both molecules for insertion, deletion, translation, and rotation were used. These simulations were also performed at 300 K for 1 500 000 steps. This process here is referred to as the simulations in presence of ethanol. More details on computational methods are discussed in Section S3 of the ESI.† In the absence of ethanol in GCMC simulations the uptake of 5-FU, IBU and

**Table 2** Maximum simulated uptake in the absence and presence of ethanol compared to our experimental uptake of 5-FU, IBU and HU in HKUST-1, NH<sub>2</sub>-MIL-53 and UiO-AZB

	Maximum simulated uptake in the presence of ethanol ( $\text{mg g}^{-1}$ )			Maximum simulated uptake in the absence of ethanol ( $\text{mg g}^{-1}$ )			Maximum experimental uptake ( $\text{mg g}^{-1}$ )		
	5-FU	IBU	HU	5-FU	IBU	HU	5-FU	IBU	HU
HKUST-1	174.7	86.1	564.2	886.9	1118.7	943.2	150 ± 10	130 ± 20	300 ± 70
NH <sub>2</sub> -MIL-53(Al)	36.4	23.3	221.6	502.8	466.6	510.9	190 ± 90	100 ± 10	440 ± 150
UiO-AZB	397.8	238.6	1071.9	1534.3	1660.3	1620.3	120 ± 20	180 ± 40	290 ± 20



HU in Cu-BTC was  $886.86 \text{ mg g}^{-1}$ ,  $1118.73 \text{ mg g}^{-1}$  and  $943.22 \text{ mg g}^{-1}$ , respectively. In presence of ethanol, the maximum simulated uptake of 5-FU, IBU and HU in HKUST-1 decreased to  $174.7 \text{ mg g}^{-1}$ ,  $86.05 \text{ mg g}^{-1}$ , and  $564.21 \text{ mg g}^{-1}$ , respectively, suggesting that solvent occupies MOF pores during drug loading. The results are in qualitative agreement with our drug loading experiments, performed in the presence of ethanol that showed the maximum adsorption of  $150 \pm 10 \text{ mg g}^{-1}$ ,  $130 \pm 20 \text{ mg g}^{-1}$  and  $300 \pm 70 \text{ mg g}^{-1}$  for 5-FU, IBU and HU in HKUST-1, respectively. For NH<sub>2</sub>-MIL-53 the maximum simulated uptake of 5-FU, IBU and HU in the absence of ethanol was

$502.77 \text{ mg g}^{-1}$ ,  $466.59 \text{ mg g}^{-1}$  and  $510.92 \text{ mg g}^{-1}$ , respectively. However, in the presence of ethanol the uptake was  $36.43 \text{ mg g}^{-1}$ ,  $23.32 \text{ mg g}^{-1}$  and  $221.61 \text{ mg g}^{-1}$ , respectively. In the experiments, uptake of 5-FU, IBU and HU in NH<sub>2</sub>-MIL-53 was  $190 \pm 90 \text{ mg g}^{-1}$ ,  $100 \pm 10 \text{ mg g}^{-1}$  and  $440 \pm 150 \text{ mg g}^{-1}$ , which was significantly higher to that of calculated adsorption in our GCMC simulations. We attribute the higher adsorption to the breathing behavior of NH<sub>2</sub>-MIL-53, which can be controlled and instigated by adsorbate loading.<sup>46–50</sup> Thus, due to its breathable nature, in our experiments, the pores in NH<sub>2</sub>-MIL-53 might open in the presence of ethanol and drug




Fig. 1 Snapshots of adsorbed 5-FU molecules in (a) and (b) HKUST-1, (c) and (d) NH<sub>2</sub>-MIL-53, (e) and (f) UiO-AZB without ethanol (left) and with ethanol (right). (5-FU is represented in red and ethanol in green).



molecules, resulting in higher adsorption of drug molecules compared to our simulations, which do not account for breathability.<sup>46</sup>

In the case of UiO-AZB, in GCMC simulations performed in the absence of ethanol, the uptake of 5-FU, IBU and HU was 1534.32 mg g<sup>-1</sup>, 1660.26 mg g<sup>-1</sup> and 1620.30 mg g<sup>-1</sup>, respectively. On the other hand, in the presence of ethanol adsorption decreased to 397.78 mg g<sup>-1</sup>, 238.65 mg g<sup>-1</sup>, and 1071.89 mg g<sup>-1</sup>, respectively. In our experiments, the uptake of 5-FU, IBU and HU in UiO-AZB was 120 ± 20 mg g<sup>-1</sup>, 180 ± 40 mg g<sup>-1</sup>, and 290 ± 20 mg g<sup>-1</sup>, respectively. Experimentally, to access the larger interior pore (*ca.* 13.7 Å) of UiO-AZB, drug molecules must first diffuse through the smaller exterior pores (*ca.* 11.9 Å and 10.8 Å). However, diffusion of larger IBU molecules compared to smaller ethanol can be hindered as IBU may block the entrance for the larger interior pore.<sup>32</sup> In addition, in presence of ethanol, displacing ethanol in these pores becomes intricate in the experiments.<sup>29</sup> In GCMC simulations, however, all the pores are accessible to drug molecules, which may result in quantitatively higher adsorption than experiments. To further investigate the origin of the notably higher adsorption of 5-FU, IBU, and HU in UiO-AZB, in our GCMC simulations, we calculated the number of drug molecules adsorbed in different pores. We found that 13.7 Å sized (interior) pore adsorbed 7.21 molecules of IBU, while the exterior pores had 4.8 IBU molecules. Adsorption in the exterior pores accounts for the 109.15 (mg g<sup>-1</sup>) adsorption and is ~40% lower compared to our experimental adsorption of IBU in UiO-AZB. This higher adsorption in experiments can be attributed to the stronger interaction of the carboxylic group

with the defect sites on the zirconium nodes of the UiO-AZB in our experiments.<sup>51,52</sup> Similarly, the adsorption of 5-FU and HU in the exterior pores was 8.59 and 72.86 molecules accounting for 121.92 mg g<sup>-1</sup> and 605.41 mg g<sup>-1</sup>. Thus, the adsorption of 5-FU and HU is within 2% and 110% to that of experimentally measured adsorption, respectively. This further suggests that the both 5-FU and HU might have been only adsorbed in the exterior pores of UiO-AZB in our experiments.

In general, maximum uptake capacity for all three drugs follows the trend HU > 5-FU > IBU, which can be attributed to their size. The smaller sized molecules (*e.g.* HU) are adsorbed more readily compared to the larger sized molecules (*e.g.* IBU). To further investigate the drug adsorption sites in the MOFs, we visually inspected the simulation trajectories. The snapshots shown in Fig. 1 suggest that in the presence of ethanol, the preferential site for drug adsorption is the interface between ethanol and MOF, while ethanol is adsorbed at the core of the MOF pores. In the absence of solvent, drug molecules can also be adsorbed at the core of MOF pores. We found that the smallest pore of HKUST-1 (*ca.* 5 Å) is occupied by only smaller molecules like ethanol, HU and 5-FU. In general, drugs are strongly confined in the one-dimensional pore of NH<sub>2</sub>-MIL-53 as shown in Fig. 1(c) and (d).

To quantify the atomic-level structure and local arrangement of specific atoms of drugs and solvent in MOFs, we performed radial distribution function (RDF) analysis.<sup>53,54</sup> Fig. 2(a)–(c) show the RDF of metal atoms in HKUST-1, NH<sub>2</sub>-MIL-53 and UiO-AZB, respectively, with selected atoms of 5-FU (oxygen, nitrogen and fluorine), IBU (all atoms of carboxylic group) and




Fig. 2 Radial distribution functional (RDF) analysis of selected atoms of drugs (i) 5-FU, (ii) IBU and (iii) HU with unsaturated metal sites of (a) HKUST-1, (b) NH<sub>2</sub>-MIL-53 and (c) UiO-AZB.



HU (nitrogen and oxygens). See ESI Fig. S1† for the definition/names of drug atoms. The first peak for Cu–O1, Cu–N2, and Cu–F1 pairs appears at 2.89 Å, 3.59 Å, and 3.54 Å, respectively (Fig. 2(a)(i)). The distances suggest a stronger structural correlation of Cu with O1 atoms compared to with N2 and F1 atoms of 5-FU. Indeed, Cu metal atoms are expected to bind stronger to more polar oxygen sites (*i.e.*, the O1 of 5-FU).<sup>55</sup> Similarly, peaks for IBU and HU suggest a stronger correlation between Cu–OH\_ib and Cu–O2 pairs, respectively (Fig. 2(a)(ii) and (iii)), suggesting stronger binding of hydroxyl groups with the copper metal sites.

In the case of NH<sub>2</sub>-MIL-53, a strong structural correlation between Al and –NH sites (N2 atom of 5-FU) is apparent compared to the correlations between Al and F1 and between Al and O1 atoms of 5-FU (Fig. 2(b)(i)). A stronger affinity of –COOH group of IBU and –NH<sub>2</sub> group of HU with Al of NH<sub>2</sub>-MIL-53 can be observed from their RDFs. Similarly, for UiO-AZB the Zr has stronger structural correlation with O1 compared to the F1 and N2 of 5-FU (Fig. 2(c)(i)). The carboxylic group of IBU didn't show any structural correlation with the Zr metal sites, which could be because Zr is not exposed in UiO-AZB.<sup>56,57</sup> However, the Zr metal site shows strongly ordered structure with –NH<sub>2</sub> groups of HU (Fig. 2(c)(iii)), thus exhibiting strong affinity towards it. The 1<sup>st</sup> peak distances of drug atoms with MOF follows the order HKUST-1 > NH<sub>2</sub>-MIL-53 > UiO-AZB, which can be accredited to the decreasing order of exposure of unsaturated metal atoms of MOFs.<sup>32,58,59</sup> Fig. S22 and S23 of ESI† describes the RDF of selected atoms of drugs with oxygen and nitrogen present in the MOF structures. Here, we observe that atom-pairs that have the

potential to form hydrogen bonds have stronger structural correlations as compared to RDFs with unsaturated metal sites in the MOF.<sup>24</sup> For example, the oxygen atoms of drugs and nitrogen in the –NH<sub>2</sub> functional groups in MOF can serve as hydrogen bond donors and acceptors, respectively, resulting in strong structural correlations.<sup>60,61</sup>

Further, the RDFs calculated for drugs in absence of ethanol show larger intensities of second and third peaks as in Fig. S24 of ESI,† which suggests that the most of the drugs are adsorbed in an empty pore volume. More details on structural correlations can be found out in Section S4 of ESI.†

The adsorption isotherms of drugs, the knowledge of preferred drug adsorption sites and the effect of solvent on drug adsorption at a range of different pressures still remains unexplored. Both temperature and pressure is known to play an important role in both drug solubility in a solvent as well as in its loading and drug release.<sup>62,63</sup> The study of dependence of drug uptake on pressure is important as it may allow us to tune the amount of drug adsorbed in MOFs by simply tuning the surrounding pressure.<sup>62</sup> As we have used three MOFs and three drugs with different stability and solubility, respectively, we have used a wide range of pressure to study drug adsorption. Specifically, we calculated adsorption isotherms in the external pressure range of 10<sup>–12</sup> to 10<sup>6</sup> pascal at 27 °C in presence and absence of ethanol using GCMC simulations. These results are shown in Fig. 3. At atmospheric pressure, drug adsorption, in the presence of ethanol, follows the following trend: UiO-AZB > HKUST-1 > NH<sub>2</sub>-MIL-53, which is consistent with the PSD results, surface area, and surface chemistry of MOFs. In general,




Fig. 3 Adsorption isotherm of the drugs in the presence (red triangles) and absence (blue squares) of ethanol in (a) HKUST-1, (b) NH<sub>2</sub>-MIL-53 and (c) UiO-AZB. Adsorption of ethanol is also shown (green triangles).



at high pressure ( $>10^2$  Pa), drug adsorption in all frameworks is higher in the absence of ethanol. As we increase the external pressure in simulations in the presence of ethanol, adsorption of drug molecules decreases while ethanol increases. Interestingly, at low pressures ( $<10^{-2}$  Pa), adsorption of drug molecules is similar in the presence and absence of ethanol. The phenomenon is attributed to stronger drug–MOF electrostatic interactions compared to drug–solvent interactions at low pressures.<sup>24</sup> IBU in HKUST-1 was adsorbed at lower pressure compared to both 5-FU and HU, which can be attributed to the stronger electrostatic interactions between IBU and HKUST-1. All three selected drugs were adsorbed in  $\text{NH}_2$ -MIL-53 at reasonably lower pressures, which can be attributed to its smaller pore size and strong electrostatic interactions through the  $-\text{NH}_2$  functional group. Due to stronger electrostatic interactions between 5-FU and IBU with UiO-AZB, they are both adsorbed at lower pressures compared to HU. In general,  $\text{NH}_2$ -MIL-53 starts adsorbing all three drug molecules at lower pressure compared to UiO-AZB and HKUST-1. This could be because in addition to the electrostatic interactions,  $\text{NH}_2$ -MIL-53's smaller pore size can also play a significant role in enhancing drug adsorption.<sup>64</sup>

The host–adsorbate energy ( $U_{\text{HA}}$ ) can be a major contributing factor in determining the adsorption of adsorbate drug and solvent molecules in MOFs.<sup>29</sup> The total potential energy of drugs in a MOF (*i.e.*, total sum of host–adsorbate and adsorbate–adsorbate energy) regulates the drug entrapment and release mechanism.<sup>24</sup> Therefore, by using the production run of the last 500 000 GCMC cycles, we calculated  $U_{\text{HA}}$  for all the systems at all simulated pressures as presented in Fig. 4. In general,  $U_{\text{HA}}$  decreases with increase in the number of adsorbate molecules in a MOF. In the case of all MOFs, the  $U_{\text{HA}}$  decreases with

increasing pressure up to a certain value, and then it remains almost constant before and after the ethanol molecules are adsorbed in the MOFs. However, in all MOFs, at higher pressures adsorption of ethanol molecules increases compared to drug molecules, resulting in higher contribution of ethanol–MOF interactions in  $U_{\text{HA}}$ . At these high pressures the host–adsorbate interaction energy for all three MOFs follows the trend  $\text{HU} + \text{ethanol} < 5\text{-FU} + \text{ethanol} < \text{IBU} + \text{ethanol}$ . This could be because, at high pressure, adsorption is dependent on the size of adsorbate molecules, and as HU is the smallest among all three drugs, more HU molecules are adsorbed.<sup>65–68</sup> As expected,  $U_{\text{HA}}$  was zero when no drug was adsorbed in HKUST-1 and UiO-AZB. However, for  $\text{NH}_2$ -MIL-53 a non-zero  $U_{\text{HA}}$  was observed at the lowest calculated pressures, which was attributed to the non-zero drug adsorption. Specifically, for HU with  $\text{NH}_2$ -MIL-53, the lower pressure range ( $<10^{-8}$  Pa) shows larger peaks despite similar drug adsorption, which can be attributed to preferential electrostatic interactions within drugs and smaller pore size MOF.<sup>24</sup> Moreover, despite the decrease in the adsorption of drugs at higher pressures ( $>10^4$  Pa), the energy fluctuates around a certain constant value, indicating that ethanol–MOF energy contribution in  $U_{\text{HA}}$  increases at higher pressure. For all three drugs, both at low and high pressures, the general trend of interaction energy is as follows:  $\text{NH}_2$ -MIL-53  $<$  UiO-AZB  $<$  HKUST-1. Indeed, at low pressure the number of drug molecules adsorbed in  $\text{NH}_2$ -MIL-53 is higher compared to the other two MOFs. This can be attributed to stronger interactions between  $\text{NH}_2$ -MIL-53, and drug and ethanol molecules due to its smaller pores.<sup>24</sup> However, at high pressure the number of drug molecules adsorbed in MOFs is as follows:  $\text{UiO-AZB} >$  HKUST-1  $>$   $\text{NH}_2$ -MIL-53, suggesting that adsorption increases with increase in MOFs pore size.




Fig. 4 Host (MOF)–adsorbate (drug + ethanol) interaction energy ( $U_{\text{HA}}$ ) of all systems understudy.



## Conclusions

A combined computational and experimental study aimed to unravel the effect of solvent on drug adsorption in MOFs was carried out. We performed GCMC simulations to study adsorption of 5-FU, IBU and HU in UiO-AZB, HKUST-1 and NH<sub>2</sub>-MIL-53 MOFs in the presence and absence of ethanol at a range of pressures. Drug adsorption in the absence of ethanol was significantly overestimated when compared to experimental results. In the presence of ethanol, simulated adsorption showed better agreement with our experimentally measured drug adsorption at 300 K and 10<sup>5</sup> Pa. In general, at high pressures, the maximum uptake capacity for all MOFs, in the presence and absence of ethanol, was proportional to the size of the drug, with HU showing consistently higher adsorption than 5-FU and IBU. We also found that in the presence of ethanol at 10<sup>5</sup> Pa, drug molecules are adsorbed at the interface of MOF and ethanol through stronger structural correlation with the MOF metal atoms. In the absence of ethanol, however, drugs can be adsorbed inside the MOF pores. Interestingly, at lower pressures (<10<sup>-4</sup> Pa) drug adsorption in the presence and absence of solvent was driven by electrostatic interactions between drugs and MOFs. As a result, solvent plays a critical role in the drug adsorption at atmospheric pressure while it does not have any impact at lower pressures. The host-adsorbate interaction ( $U_{HA}$ ) energy was affected by the drug size, MOF pore diameter, and simulated pressure. At low pressure, with decrease in pore size and increase in drug size  $U_{HA}$  decreases. On the other hand, at high pressure,  $U_{HA}$  decreases up to a certain value and then stabilizes, which also decreases with the pore size while the adsorption of drug molecules increases. Our study implies that solvent is very critical in adsorption of small molecules in porous materials and the impact of solvent on small molecules should be considered when designing new materials investigation, both experimentally and computationally.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

Authors acknowledge Advanced Research Computing (ARC), Virginia Tech for providing the computational resources. This research used resources of the National Energy Research Scientific Computing Center (NERSC), a U.S. Department of Energy Office of Science User Facility located at Lawrence Berkeley National Laboratory, operated under Contract No. DE-AC02-05CH11231. This work was made possible by the use of Virginia Tech's Materials Characterization Facility, which is supported by the Institute for Critical Technology and Applied Science, the Macromolecules Innovation Institute, and the Office of the Vice President for Research and Innovation. The authors are also thankful to Hazel Thorpe Carman and George Gay Carman Trust for financial support.

## References

- 1 A. Ben-Naim, *Biopolymers*, 1990, **29**, 567–596.
- 2 F. Gräter, P. Heider, R. Zangi and B. J. Berne, *J. Am. Chem. Soc.*, 2008, **130**, 11578–11579.
- 3 P. A. Bartlett, N. Yusuff, A. C. Rico and M. K. Lindvall, *J. Am. Chem. Soc.*, 2002, **124**, 3853–3857.
- 4 C.-P. Li and M. Du, *Chem. Commun.*, 2011, **47**, 5958–5972.
- 5 X. Yang and A. E. Clark, *Inorg. Chem.*, 2014, **53**, 8930–8940.
- 6 N. Perunov and J. L. England, *Protein Sci.*, 2014, **23**, 387–399.
- 7 M. M. Teeter, *Annu. Rev. Biophys. Biophys. Chem.*, 1991, **20**, 577–600.
- 8 B. U. Riebesehl, in *The Practice of Medicinal Chemistry*, ed. C. G. Wermuth, D. Aldous, P. Raboisson and D. Rognan, Academic Press, San Diego, 4th edn, 2015, pp. 699–722.
- 9 Y. Liu, Y. Zhao and X. Chen, *Theranostics*, 2019, **9**, 3122–3133.
- 10 M.-X. Wu and Y.-W. Yang, *Adv. Mater.*, 2017, **29**, 1606134.
- 11 Y. Sun, L. Zheng, Y. Yang, X. Qian, T. Fu, X. Li, Z. Yang, H. Yan, C. Cui and W. Tan, *Nano-Micro Lett.*, 2020, **12**, 103.
- 12 J. G. Vitillo and G. Ricchiardi, *J. Phys. Chem. C*, 2017, **121**, 22762–22772.
- 13 I. Erucar and S. Keskin, *Ind. Eng. Chem. Res.*, 2016, **55**, 1929–1939.
- 14 D. Cunha, M. Ben Yahia, S. Hall, S. R. Miller, H. Chevreau, E. Elkaïm, G. Maurin, P. Horcajada and C. Serre, *Chem. Mater.*, 2013, **25**, 2767–2776.
- 15 I. Erucar and S. Keskin, *J. Mater. Chem. B*, 2017, **5**, 7342–7351.
- 16 J.-Q. Liu, X.-F. Li, C.-Y. Gu, J. C. S. da Silva, A. L. Barros, S. Alves Jr, B.-H. Li, F. Ren, S. R. Batten and T. A. Soares, *Dalton Trans.*, 2015, **44**, 19370–19382.
- 17 P. Horcajada, C. Serre, G. Maurin, N. A. Ramsahye, F. Balas, M. Vallet-Regí, M. Sebban, F. Taulelle and G. Férey, *J. Am. Chem. Soc.*, 2008, **130**, 6774–6780.
- 18 A. U. Czaja, N. Trukhan and U. Müller, *Chem. Soc. Rev.*, 2009, **38**, 1284–1293.
- 19 M. Ranocchiari and J. A. van Bokhoven, *Phys. Chem. Chem. Phys.*, 2011, **13**, 6388–6396.
- 20 B. Wang, L.-H. Xie, X. Wang, X.-M. Liu, J. Li and J.-R. Li, *Green Energy Environ.*, 2018, **3**, 191–228.
- 21 H. Li, K. Wang, Y. Sun, C. T. Lollar, J. Li and H.-C. Zhou, *Mater. Today*, 2018, **21**, 108–121.
- 22 R. Seetharaj, P. V. Vandana, P. Arya and S. Mathew, *Arab. J. Chem.*, 2019, **12**, 295–315.
- 23 B. Zhang, J. Zhang, C. Liu, X. Sang, L. Peng, X. Ma, T. Wu, B. Han and G. Yang, *RSC Adv.*, 2015, **5**, 37691–37696.
- 24 M. C. Bernini, D. Fairen-Jimenez, M. Pasinetti, A. J. Ramirez-Pastor and R. Q. Snurr, *J. Mater. Chem. B*, 2014, **2**, 766–774.
- 25 M. Gomar and S. Yeganegi, *Microporous Mesoporous Mater.*, 2017, **252**, 167–172.
- 26 F. Li, B. Li, C. Wang, Y. Zeng, J. Liu, C.-Y. Gu, P. Lu and L. Mei, *RSC Adv.*, 2016, **6**, 47959–47965.
- 27 L. Bei, L. Yuanhui, L. Zhi and C. Guangjin, *Acta Chim. Sin.*, 2014, **72**, 942–948.
- 28 R. Babarao and J. Jiang, *J. Phys. Chem. C*, 2009, **113**, 18287–18291.



- 29 Y. G. Proenza and R. L. Longo, *J. Chem. Inf. Model.*, 2020, **60**, 644–652.
- 30 L. R. Parent, C. Huy Pham, J. P. Patterson, M. S. Denny, S. M. Cohen, N. C. Gianneschi and F. Paesani, *J. Am. Chem. Soc.*, 2017, **139**, 13973–13976.
- 31 Y. Li, X. Li, Q. Guan, C. Zhang, T. Xu, Y. Dong, X. Bai and W. Zhang, *Int. J. Nanomed.*, 2017, **12**, 1465–1474.
- 32 C. C. Epley, M. D. Love and A. J. Morris, *Inorg. Chem.*, 2017, **56**, 13777–13784.
- 33 M. Jorge, M. Fischer, J. R. B. Gomes, C. Siquet, J. C. Santos and A. E. Rodrigues, *Ind. Eng. Chem. Res.*, 2014, **53**, 15475–15487.
- 34 M. Fischer, J. R. B. Gomes, M. Fröba and M. Jorge, *Langmuir*, 2012, **28**, 8537–8549.
- 35 J. Rouquerol, D. Avnir, C. W. Fairbridge, D. H. Everett, J. M. Haynes, N. Pernicone, J. D. F. Ramsay, K. S. W. Sing and K. K. Unger, *J. Macromol. Sci., Part A: Pure Appl. Chem.*, 2009, **66**, 1739–1758.
- 36 N. Al-Janabi, P. Hill, L. Torrente-Murciano, A. Garforth, P. Gorgojo, F. Siperstein and X. Fan, *Chem. Eng. J.*, 2015, **281**, 669–677.
- 37 S. Yang, L. Peng, D. T. Sun, M. Asgari, E. Oveisi, O. Trukhina, S. Bulut, A. Jamali and W. L. Queen, *Chem. Sci.*, 2019, **10**, 4542–4549.
- 38 K.-J. Kim, Y. J. Li, P. B. Kreider, C.-H. Chang, N. Wannemacher, P. K. Thallapally and H.-G. Ahn, *Chem. Commun.*, 2013, **49**, 11518–11520.
- 39 H. K. Kim, W. S. Yun, M.-B. Kim, J. Y. Kim, Y.-S. Bae, J. Lee and N. C. Jeong, *J. Am. Chem. Soc.*, 2015, **137**, 10009–10015.
- 40 J. L. C. Rowsell and O. M. Yaghi, *J. Am. Chem. Soc.*, 2006, **128**, 1304–1315.
- 41 M. Schlesinger, S. Schulze, M. Hietschold and M. Mehring, *Microporous Mesoporous Mater.*, 2010, **132**, 121–127.
- 42 J. Gascon, U. Aktay, M. D. Hernandez-Alonso, G. P. M. van Klink and F. Kapteijn, *J. Catal.*, 2009, **261**, 75–87.
- 43 S. Rostamnia and M. Jafari, *Appl. Organomet. Chem.*, 2017, **31**, e3584.
- 44 L. Bolinois, T. Kundu, X. Wang, Y. Wang, Z. Hu, K. Koh and D. Zhao, *Chem. Commun.*, 2017, **53**, 8118–8121.
- 45 X. Cheng, A. Zhang, K. Hou, M. Liu, Y. Wang, C. Song, G. Zhang and X. Guo, *Dalton Trans.*, 2013, **42**, 13698.
- 46 O. Weser and V. Veryazov, *Front. Chem.*, 2017, **5**, 111.
- 47 A. Vimont, A. Travert, P. Bazin, J.-C. Lavalley, M. Daturi, C. Serre, G. Férey, S. Bourrelly and P. L. Llewellyn, *Chem. Commun.*, 2007, 3291.
- 48 L. Hamon, H. Leclerc, A. Ghoufi, L. Oliviero, A. Travert, J.-C. Lavalley, T. Devic, C. Serre, G. Férey, G. De Weireld, A. Vimont and G. Maurin, *J. Phys. Chem. C*, 2011, **115**, 2047–2056.
- 49 D. Bousquet, F.-X. Coudert, A. G. J. Fossati, A. V. Neimark, A. H. Fuchs and A. Boutin, *J. Chem. Phys.*, 2013, **138**, 174706.
- 50 A. Schneemann, V. Bon, I. Schwedler, I. Senkovska, S. Kaskel and R. A. Fischer, *Chem. Soc. Rev.*, 2014, **43**, 6062–6096.
- 51 J. J. Wardzala, J. P. Ruffley, I. Goodenough, A. M. Schmidt, P. B. Shukla, X. Wei, A. Baguettey, M. De Souza, P. Das, D. J. Thompson, C. J. Karwacki, C. E. Wilmer, E. Borguet, N. L. Rosi and J. K. Johnson, *J. Phys. Chem. C*, 2020, **124**, 28469–28478.
- 52 S. Wang, G. Zhou, Y. Sun and L. Huang, *AIChE J.*, 2021, **67**(3), DOI: 10.1002/aic.17035.
- 53 S. A. Deshmukh, S. K. R. S. Sankaranarayanan, K. Suthar and D. C. Mancini, *J. Phys. Chem. B*, 2012, **116**, 2651–2663.
- 54 S. A. Deshmukh, Z. Li, G. Kamath, K. J. Suthar, S. K. R. S. Sankaranarayanan and D. C. Mancini, *Polymer*, 2013, **54**, 210–222.
- 55 C. H. Hendon and A. Walsh, *Chem. Sci.*, 2015, **6**, 3674–3683.
- 56 G. Gonzalez, A. Sagarzazu and T. Zoltan, *J. Drug Delivery*, 2013, **2013**, 803585.
- 57 R. Bueno-Perez, A. Martin-Calvo, P. Gómez-Álvarez, J. J. Gutiérrez-Sevillano, P. J. Merklings, T. J. H. Vlugt, T. S. van Erp, D. Dubbeldam and S. Calero, *Chem. Commun.*, 2014, **50**, 10849–10852.
- 58 S. S. Chui, *Science*, 1999, **283**, 1148–1150.
- 59 E. Stavitski, E. A. Pidko, S. Couck, T. Remy, E. J. M. Hensen, B. M. Weckhuysen, J. Denayer, J. Gascon and F. Kapteijn, *Langmuir*, 2011, **27**, 3970–3976.
- 60 K. A. Connors, *Chem. Rev.*, 1997, **97**, 1325–1358.
- 61 J. Zhong, Y. Zhao, L. Li, H. Li, J. S. Francisco and X. C. Zeng, *J. Am. Chem. Soc.*, 2015, **137**, 12070–12078.
- 62 K. Jiang, L. Zhang, Q. Hu, D. Zhao, T. Xia, W. Lin, Y. Yang, Y. Cui, Y. Yang and G. Qian, *J. Mater. Chem. B*, 2016, **4**, 6398–6401.
- 63 N. Kaur, P. Tiwari, K. S. Kapoor, A. K. Saini, V. Sharma and S. M. Mobin, *CrystEngComm*, 2020, **22**, 7513–7527.
- 64 J. R. Karra and K. S. Walton, *Langmuir*, 2008, **24**, 8620–8626.
- 65 S. Li, Y. G. Chung and R. Q. Snurr, *Langmuir*, 2016, **32**, 10368–10376.
- 66 H. Daglar and S. Keskin, *J. Phys. Chem. C*, 2018, **122**, 17347–17357.
- 67 S. Keskin, in *Metal-Organic Frameworks*, InTech, 2016.
- 68 S. Gautam and D. Cole, *Nanomaterials*, 2020, DOI: 10.3390/nano10112274.

